技术简介

本技术利用生物反应器无血清全悬浮培养BHK-21细胞规模化生产口蹄疫疫苗年产值达15亿元以上。拥有整体工艺和核心技术的自主知识产权，技术的能耗低、废物少和自动化程度高，农业农村部科技发展中心的成果评价结论为“整体水平达到了国内领先水平，无血清悬浮细胞培养技术达到国际领先水平”。

Introduction

This technology uses bioreactor serum-free full suspension culture of BHK-21 cells to produce foot-and.mouth disease vaccine on a large scale with an annual output value of more than 1.5 billion yuan. The technologyhas independent intellectual property rights of the overall process and core technology, with low energyconsumption, less waste and high automation. The Development Center of Science and Technology, MARA judgedthat "The overall level has reached the domestic leading level, and the serum-free cell suspension culturetechnologyhas reached the international leading level".